Isolation of nanomolar scFvs of non-human primate origin, cross-neutralizing botulinum neurotoxins A1 and A2 by targeting their heavy chain

BMC Biotechnology

Volumn 15, Issue 1, 2015, Pages

  Avril, Arnaud ^a   Miethe, Sebastian ^b   Popoff, Michel R ^c   Mazuet, Christelle ^c   Chahboun, Siham ^a   Rasetti Escargueil, Christine ^d   Sesardic, Dorothea ^d   Thullier, Philippe ^a   Hust, Michael ^b   Pelat, Thibaut ^a,e  

^a INSTITUT DE RECHERCHE BIOMÉDICALE DES ARMÉES   (France)

^b TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

^c INSTITUT PASTEUR   (France)

^d NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^e BIOTEM   (France)

Author keywords

AntiBotABE; Biological warfare agents; Botulinum neurotoxin; Clostridium botulinum; Macaques; Neutralizing antibodies; Non human primates; Recombinant antibodies; scFv

Indexed keywords

BIOLOGICAL WARFARE; CHAINS; CHEMICAL WARFARE; CLOSTRIDIUM; DISEASE CONTROL; MAMMALS;

ANTIBOTABE; BIOLOGICAL WARFARE AGENTS; BOTULINUM NEUROTOXINS; CLOSTRIDIUM BOTULINUM; MACAQUES; NEUTRALIZING ANTIBODIES; NON-HUMAN PRIMATE; RECOMBINANT ANTIBODY; SCFV;

ANTIBODIES;

A1HC38 ANTIBODY; ANTIBODY; BOTULINUM NEUROTOXIN A1; BOTULINUM NEUROTOXIN A2; BOTULINUM TOXIN A; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; BIOLOGICAL WARFARE AGENT; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BIOTECHNOLOGICAL PRODUCTION; CONTROLLED STUDY; CROSS NEUTRALIZATION; CROSS REACTION; HEAVY CHAIN; HEMIDIAPHRAGM; IMMUNOLOGICAL PARAMETERS; MACACA; MALE; MOUSE; NONHUMAN; PHAGE DISPLAY; PHRENIC NERVE; ANIMAL; BIOLOGICAL WARFARE AGENT; CHEMISTRY; CLOSTRIDIUM BOTULINUM; GENETICS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; BIOLOGICAL WARFARE AGENTS; BOTULINUM TOXINS, TYPE A; CLOSTRIDIUM BOTULINUM; HUMANS; MACACA; MALE; MICE; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES;

EID: 84942033230     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/s12896-015-0206-0     Document Type: Article

References (50)

1. Lacy DB, Stevens RC. Sequence homology and structural analysis of the clostridial neurotoxins. J Mol Biol. 1999;291:1091-104.
2. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA. 2001;285:1059-70.
3. Gill DM. Bacterial toxins: a table of lethal amounts. Microbiol Rev. 1982;46:86-94.
4. Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev. 1992;56:80-99.
5. Montecucco C, Schiavo G. Mechanism of action of tetanus and botulinum neurotoxins. Mol Microbiol. 1994;13:1-8.
6. Rusnak JM, Smith LA. Botulinum neurotoxin vaccines: Past history and recent developments. Hum Vaccin. 2009;5:794-805.
7. Smith LA. Botulism and vaccines for its prevention. Vaccine. 2009;27 Suppl 4:D33-9.
8. Kaji R. New and emerging indications of botulinum toxin therapy. Parkinsonism Relat Disord. 2011;17 Suppl 1:S25-7.
9. Franz DR, Pitt LM, Clayton MA, Hanes MA, Rose KJ. Efficacy of prophylactic and therapeutic administration of antitoxin for inhalation botulism. In: Botulinum Tetanus Neurotoxins Biomed Asp. New-York: Das Gupta; 1993.
10. Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med. 2006;354:462-71.
11. Black RE, Gunn RA. Hypersensitivity reactions associated with botulinal antitoxin. Am J Med. 1980;69:567-70.
12. Mayers C, Veall S, Bedford R, Holley J. Anti-immunoglobulin responses to IgG, F(ab')2, and Fab botulinum antitoxins in mice. Immunopharmacol Immunotoxicol. 2003;25:397-408.
13. Amersdorfer P, Wong C, Smith T, Chen S, Deshpande S, Sheridan R, et al. Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. Vaccine. 2002;20:1640-8.
14. Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NBM. Hamid M: scFv antibody: principles and clinical application. Clin Dev Immunol. 2012;2012:980250.
15. Adekar SP, Takahashi T, Jones RM, Al-Saleem FH, Ancharski DM, Root MJ, et al. Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain. PLoS One. 2008;3, e3023.
16. Avril A, Froude JW, Mathieu J, Pelat T, Thullier P. Isolation of antibodies from non-human primates for clinical use. Curr Drug Discov Technol. 2014;11(1):20-7.
17. Pelat T, Avril A, Chahboun S, Mathieu J, Thullier P. Development of Anti-Toxins Antibodies for Biodefense. Bioterrorism Biodefense. 2011;S7:001.
18. Laffly E, Danjou L, Condemine F, Vidal D, Drouet E, Lefranc M-P, et al. Selection of a macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694. Antimicrob Agents Chemother. 2005;49:3414-20.
19. Rülker T, Voß L, Thullier P, O' Brien LM, Pelat T, Perkins SD, et al. Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV in vitro and in vivo. PLoS One. 2012;7, e37242.
20. Pelat T, Hust M, Laffly E, Condemine F, Bottex C, Vidal D, et al. High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation. Antimicrob Agents Chemother. 2007;51:2758-64.
21. Pelat T, Hust M, Hale M, Lefranc M-P, Dübel S, Thullier P. Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity. BMC Biotechnol. 2009;9:60.
22. Chahboun S, Hust M, Liu Y, Pelat T, Miethe S, Helmsing S, et al. Isolation of a nanomolar scFv inhibiting the endopeptidase activity of botulinum toxin A, by single-round panning of an immune phage-displayed library of macaque origin. BMC Biotechnol. 2011;11:113.
23. Miethe S, Rasetti-Escargueil C, Liu Y, Chahboun S, Pelat T, Avril A, et al. Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library. MAbs. 2014;6:446-59.
24. AntiBotABE official website [ http://www.antibotabe.com ]
25. Schütte M, Thullier P, Pelat T, Wezler X, Rosenstock P, Hinz D, et al. Identification of a putative Crf splice variant and generation of recombinant antibodies for the specific detection of Aspergillus fumigatus. PLoS One. 2009;4:e6625.
26. Hust M, Meyer T, Voedisch B, Rülker T, Thie H, El-Ghezal A, et al. A human scFv antibody generation pipeline for proteome research. J Biotechnol. 2011;152:159-70.
27. Kirsch MI, Hülseweh B, Nacke C, Rülker T, Schirrmann T, Marschall H-J, et al. Development of human antibody fragments using antibody phage display for the detection and diagnosis of Venezuelan equine encephalitis virus (VEEV). BMC Biotechnol. 2008;8:66.
28. Pelat T, Bedouelle H, Rees AR, Crennell SJ, Lefranc M-P, Thullier P. Germline humanization of a non-human primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering. J Mol Biol. 2008;384:1400-7.
29. Thullier P, Huish O, Pelat T, Martin ACR. The humanness of macaque antibody sequences. J Mol Biol. 2010;396:1439-50.
30. Kalb SR, Lou J, Garcia-Rodriguez C, Geren IN, Smith TJ, Moura H, et al. Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies. PLoS One. 2009;4, e5355.
31. Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, et al. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A. 2002;99:11346-50.
32. Cheng LW, Stanker LH, Henderson 2nd TD, Lou J, Marks J. Antibody protection against botulinum neurotoxin intoxication in mice. Infect Immun. 2009;77:4305-13.
33. Conway JO, Sherwood LJ, Collazo MT, Garza JA, Hayhurst A. Llama single domain antibodies specific for the 7 botulinum neurotoxin serotypes as heptaplex immunoreagents. Plos One. 2010;5(1):e8818.
34. Dolimbek BZ, Aoki KR, Steward LE, Jankovic J, Atassi MZ. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol. 2007;44:1029-41.
35. Hill KK, Smith TJ, Helma CH, Ticknor LO, Foley BT, Svensson RT, et al. Genetic diversity among Botulinum Neurotoxin-producing clostridial strains. J Bacteriol. 2007;189:818-32.
36. Carter AT, Paul CJ, Mason DR, Twine SM, Alston MJ, Logan SM, et al. Independent evolution of neurotoxin and flagellar genetic loci in proteolytic Clostridium botulinum. BMC Genomics. 2009;10:115.
37. TM bioreactor. J Biotechnol. 2013;163(2):105-11.
38. Rasetti-Escargueil C, Liu Y, Rigsby P, Jones RGA, Sesardic D. Phrenic nerve-hemidiaphragm as a highly sensitive replacement assay for determination of functional botulinum toxin antibodies. Toxicon. 2011;57:1008-16.
39. Laffly E, Pelat T, Cédrone F, Blésa S, Bedouelle H, Thullier P. Improvement of an antibody neutralizing the anthrax toxin by simultaneous mutagenesis of its six hypervariable loops. J Mol Biol. 2008;378:1094-103.
40. USDA Animal Welfare Act (AWA). 7 U.S.C. 2131 et Seq., as amended; Health Research Extension Act of 1985 ("'Animals in Research'"). 1985.
41. National Research Council. Guide for the Care; Use of Laboratory Animals. 8th ed. Washington: The National Academies Press; 2011.
42. Tavallaie M, Chenal A, Gillet D, Pereira Y, Manich M, Gibert M, et al. Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies. FEBS Lett. 2004;572:299-306.
43. Pelat T, Hust M, Thullier P. Obtention and engineering of non-human primate (NHP) antibodies for therapeutics. Mini Rev Med Chem. 2009;9:1633-8.
44. Frenzel A, Kügler J, Wilke S, Schirrmann T, Hust M. Construction of human antibody gene libraries and selection of antibodies by phage display. Methods Mol Biol. 2014;1060:215-43.
45. Schuck P, Minton AP. Analysis of mass transport-limited binding kinetics in evanescent wave biosensors. Anal Biochem. 1996;240:262-72.
46. Alamyar E, Giudicelli V, Li S, Duroux P, Lefranc M-P. IMGT/HighV-QUEST: the IMGT® web portal for immunoglobulin (IG) or antibody and T cell receptor (TR) analysis from NGS high throughput and deep sequencing. Immunome Res. 2012;8:26.
47. The international immunogenetics information system [ http://www.imgt.org/ ]
48. Ehrenmann F, Lefranc M-P. IMGT/DomainGapAlign: the IMGT® tool for the analysis of IG, TR, MH, IgSF, and MhSF domain amino acid polymorphism. Methods Mol Biol. 2012;882:605-33.
49. University College London website for the calculation of GI and GS [ http://www.bioinf.org.uk/abs/ ]
50. Rasetti-Escargueil C, Jones RGA, Liu Y, Sesardic D. Measurement of botulinum types A, B and E neurotoxicity using the phrenic nerve-hemidiaphragm: improved precision with in-bred mice. Toxicon. 2009;53:503-11.